Bibliography
- Snider RM, Constantine JW, Lowe JA, et al. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7
- Swain CJ. Neurokinin receptor antagonists. Prog Med Chem 1998;35:57-81
- Seward EM, Swain CJ. Neurokinin antagonists. Expert Opin Ther Patents 1999;9:571-82
- Johansson A. Recent developments in the medicinal chemistry of NK2 receptor antagonists. Curr Top Med Chem 2003;3:1436-45
- Humphrey JM. Medicinal chemistry of selective neurokinin-1 antagonists. Curr Top Med Chem 2003;3:1423-35
- Rizzo CA, Anthes JC, Corboz MR, et al. Development and potential utility of dual and triple NK receptor antagonists. Curr Top Med Chem 2003;3:1410-22
- Warr D. The neurokinin1 receptor antagonist aprepitant as an antiemetic for moderately emetogenic chemotherapy. Expert Opin Pharmacother 2006;7:1653-8
- Quartara L, Altamura M. Tachykinin receptors antagonists: from research to clinic. Curr Drug Targets 2006;7:975-92
- Rumsey WL, Aharony D, Bialecki RA, et al. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors. J Pharmacol Exp Ther 2001;298:307-15
- Bernstein PR, Aharony D, Albert JS, et al. Discovery of novel, orally active dual NK1/NK2 antagonists. Bioorg Med Chem Lett 2001;11:2769-73
- AstraZeneca AB. WO2004110344 (2004)
- AstraZeneca AB. WO2006062478 (2006)
- AstraZeneca AB. WO2007037742 (2007)
- AstraZeneca AB. WO2007037743 (2007)
- AstraZeneca AB. US20070270399 (2007)
- AstraZeneca AB. US20070270400 (2007)
- AstraZeneca development pipeline [7 December 2007]. Available from: http://www.astrazeneca.com/sites/7/imagebank/typearticleparam511390/astrazeneca-Pipeline-Summary-Table-7-December.pdf